Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal

@article{Tosh2013GolimumabFT,
  title={Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal},
  author={Jonathan C Tosh and R. Archer and Sarah Davis and Matt Stevenson and J. Stevens},
  journal={PharmacoEconomics},
  year={2013},
  volume={31},
  pages={653-661}
}
  • Jonathan C Tosh, R. Archer, +2 authors J. Stevens
  • Published 2013
  • Medicine
  • PharmacoEconomics
  • As part of the National Institute for Health and Clinical Excellence (NICE) single technology appraisal (STA) process, the manufacturer of golimumab (Simponi®; Merck Sharp & Dohme, USA) was invited to submit evidence for its clinical and cost effectiveness for the treatment of rheumatoid arthritis (RA) after the failure of previous disease-modifying antirheumatic drugs (DMARDs). The School of Health and Related Research Technology Appraisal Group (ScHARR-TAG) at The University of Sheffield was… CONTINUE READING
    21 Citations
    Golimumab for the Treatment of Psoriatic Arthritis
    • 37
    The Added Value of Real-World Evidence
    • 1
    • PDF

    References

    SHOWING 1-10 OF 73 REFERENCES
    Golimumab for the Treatment of Psoriatic Arthritis
    • 37
    Alitretinoin for Severe Chronic Hand Eczema
    • 52